Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

Angiodynamics Inc. ANGO

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$320.2M
▲ 9.5% YoY
$-36.7M
$508,000

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

AngioDynamics, Inc. designs, manufactures and sells products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Its product offerings fall within two segments, Med Tech and Med Device. Within its Med Tech segment, its Thrombus Management portfolio includes the AlphaVac Mechanical Thrombectomy System, the AngioVac venous drainage cannula and circuit, and catheter directed thrombolytic devices, including the Uni-Fuse system and the Uni-Fuse+ system. Within its Med Device segment, it offers products for use during minimally invasive procedures, with product categories including angiographic catheters, guidewires, drainage catheters and micropuncture kits. It sells its devices in the United States primarily through a direct sales force and internationally through a combination of direct sales and distributor relationships. As of May 31, 2026, the company had approximately 632 full-time employees. AngioDynamics was founded in Queensbury, N.Y., in 1988, and the company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury facility.

Written from the business description in AngioDynamics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 14 July 2026. Every sentence was checked against that document before publication.

Growth

USD 320.2M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 320.2 · Net income -36.7
150M300M-100M-200M
2009201220152018202120242025
Compound annual growth
−1.9%
+1.9%
−1.0%
+2.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +1.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−11 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -12.5% · Net -11.5%
10%20%-20%-40%-60%
200920172025
ROE
FY2025 · ROE -20.8%
5%10%-20%-40%-60%
200920172025
Three returns, three denominators.

Each USD of equity lost 21 cents this year.

Cash & shareholders

USD 0.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.5
20M40M-15M-30M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 0.0
2M3M-2M-4M
2011201320152017202220242025

Total assetsUSD 267.2M
EquityUSD 170.8M
CashUSD 53.9M
Current ratio2.19×

Equity funds 64% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
ANGO, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.30.30.30.30.30.30.30.30.30.30.40.40.40.30.20.20.2
Operating income $B−0.0−0.0−0.2−0.1−0.0−0.0−0.2−0.0−0.0−0.00.0−0.00.00.0−0.00.00.0
EBITDA $B−0.0−0.0−0.2−0.0−0.0−0.0−0.2−0.0−0.0−0.00.00.00.00.0−0.00.0◌
Income tax $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.00.00.0
Net income $B−0.0−0.0−0.2−0.1−0.0−0.0−0.20.10.00.0−0.0−0.00.0−0.0−0.00.00.0
Free cash flow $B0.0−0.0−0.0−0.0−0.00.0−0.00.00.00.10.00.00.00.00.00.00.0
EPS, diluted $−0.88−0.83−4.59−1.33−0.68−0.82−4.391.640.440.14−1.21−0.090.07−0.03−0.200.320.50
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %————————————0−0−0——
ROE %−20.8−17.5−63.1−13.1−6.1−7.1−31.210.63.11.0−8.3−0.60.4−0.2−1.12.03.1
Shares out B0.040.040.040.040.040.040.040.040.040.040.040.040.040.040.030.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsMay 31
Data on record since2009

Share this section

Download image